IP Library Granted Patent US 8,802,131
Granted Patent B2
US 8,802,131 · App. 12/541,840 · Granted Aug 12, 2014

Devices and methods for delivering active agents to the osteomeatal complex

Inventors: Patrick A. Arensdorf (Palo Alto, CA); Danielle L. Biggs (Hoover, AL); Rodney Brenneman (San Juan Capistrano, CA); David B. Downie (Cupertino, CA); Donald J. Eaton (Los Altos, CA); Thomas R. Tice (Indian Springs, AL)
Assignee: Intersect ENT, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,802,131
App. No.
12/541,840
Granted
Aug 12, 2014
Kind
B2
Abstract

Described here are devices, methods, and kits for treating sinusitis and related respiratory conditions by locally delivering active agents to the osteomeatal complex over a sustained period of time. The devices may be passively fixed within the osteomeatal complex and/or include one or more features that actively fix it within the osteomeatal complex. The devices may optionally include a portion that extends into a sinus ostium, sinus cavity, and/or the nasal passage to deliver an active agent.

Claims (14)

1. A method for cannulating a portion of an osteomeatal complex comprising:

implanting and securing a portion of a cannulating device to the osteomeatal complex by piercing a portion of the osteomeatal complex with a pointed tip of the cannulating device, wherein the cannulating device comprises a lumen extending at least partially therethrough and wherein the pointed tip of the cannulating device is implanted.

2. The method of claim 1 wherein the cannulating device is configured to release one or more active agents.

3. The method of claim 2 wherein the one or more active agents comprises an anti-inflammatory agent.

4. The method of claim 3 wherein the anti-inflammatory agent comprises mometasone furoate.

5. The method of claim 3 wherein the anti-inflammatory agent comprises fluticasone propionate.

6. The method of claim 1 wherein the cannulating device comprises a polymer coating.

7. The method of claim 6 wherein the polymer coating comprises one or more active agents.

8. The method of claim 1 wherein the cannulating device comprises a biodegradable polymer.

9. The method of claim 8 wherein the biodegradable polymer comprises a lactide/glycolide polymer.

10. The method of claim 1 wherein piercing the portion of the osteomeatal complex comprises piercing an ethmoid bulla.

11. The method of claim 1 wherein piercing the portion of the osteomeatal complex comprises piercing an anterior ethmoid cell.

12. The method of claim 1 wherein the cannulating device comprises a plurality of openings in a side of the cannulating device, wherein the openings are connected to the lumen.

13. The method of claim 1 wherein piercing a portion of the osteomeatal complex comprises piercing an ethmoid bulla and a septum between the ethmoid bulla and an anterior ethmoid cell to create a channel between the ethmoid bulla and the anterior ethmoid cell.

Assignments (3)
CHANGE OF NAME Recorded Jun 1, 2010
From: SINEXUS, INC.
To: INTERSECT ENT, INC.
Reel/Frame 024467/0169 →
CONFIRMATORY ASSIGNMENT Recorded Aug 21, 2009
From: ARENSDORF, PATRICK A.; BIGGS, DANIELLE L.; BRENNEMAN, RODNEY; DOWNIE, DAVID B.; EATON, DONALD J.; TICE, THOMAS R.
To: SINEXUS, INC.
Reel/Frame 023131/0773 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2009
From: ARENSDORF, PATRICK A.; BIGGS, DANIELLE L.; BRENNEMAN, RODNEY; DOWNIE, DAVID B.; EATON, DONALD J.; TICE, THOMAS R.
To: SINEXUS, INC.
Reel/Frame 023132/0075 →
Continuity (3)
Continuation 11775157 · Jul 9, 2007
Provisional Application 60819825 · Jul 10, 2006
Related Publication 20090306624A1 · Dec 10, 2009